PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of wjscLink to Publisher's site
 
World J Stem Cells. 2009 December 31; 1(1): 30–35.
Published online 2009 December 31. doi:  10.4252/wjsc.v1.i1.30
PMCID: PMC2958105
NIHMSID: NIHMS201837

Twisting immune responses for allogeneic stem cell therapy

Abstract

Stem cell-derived tissues and organs have the potential to change modern clinical science. However, rejection of allogeneic grafts by the host’s immune system is an issue which needs to be addressed before embryonic stem cell-derived cells or tissues can be used as medicines. Mismatches in human leukocyte class I antigens and minor histocompatibility antigens are the central factors that are responsible for various graft-versus-host diseases. Traditional strategies usually involve suppressing the whole immune systems with drugs. There are many side effects associated with these methods. Here, we discuss an emerging strategy for manipulating the central immune tolerance by naturally “introducing” donor antigens to a host so a recipient can acquire tolerance specifically to the donor cells or tissues. This strategy has two distinct stages. The first stage restores the thymic function of adult patients with sex steroid inhibitory drugs (LHRH-A), keratinocyte growth factor (KGF), interleukin 7 (IL-7) and FMS-like tyrosine kinase 3 (FLT3). The second stage introduces hematopoietic stem cells and their downstream progenitors to the restored thymus by direct injection. Hematopoietic stem cells are used to introduce donor antigens because they have priority access to the thymus. We also review several clinical cases to explain this new strategy.

Keywords: Stem cell therapy, Immune response, Allogeneic grafts

INTRODUCTION

Ever since stem cells were discovered during the analysis of teratocarcinoma in 1964, stem cell-based therapy has conjured a hope for those who are suffering from previously incurable diseases, particularly degenerative diseases[1,2]. Since embryonic stem cells (ESC) are pluripotent, stem cell-derived cells and tissues are believed to be the best treatment for variety of degenerative diseases by replacing damaged tissues. However, there are still ethical and technical barriers which need to be overcome before these hopes become reality. For example, ESC-driven tumor formation is one technical barrier[3]. Immune rejection caused by foreign antigens expressed on the stem cell graft would be another major hurdle that needs an immediate solution for stem cell therapy[4-6].

Immune rejection concerns are raised when using stem cells that do not exactly match a recipient’s immune system - such as existing human embryonic stem cell (hESC) lines that are not derived from the recipient[7]. For example, Wu’s group showed that transplanted ESCs died within about 7 to 10 d in mice with functioning immune systems while they survived and proliferated in immunocompromised mice[5]. They showed that secondary injections of ESCs into the immune-normal mice led to more rapid cell death, suggesting the immune system became more efficient at recognizing and rejecting the second dose of ESCs. It is believe that ESCs express certain surface proteins that trigger the recipient’s immune system to attack donor ESCs as they differentiate into more-specialized tissues. Thus the first ESC injection primed the immune system to recognize the foreign molecules, and the immune system responded even more quickly to the second ESC injection. Combination of two antirejection compounds - tacrolimus and sirolimus - allowed the cells to survive for up to 28 d in mice with normal immune systems[4,5]. This is consistent with strategies to prevent T cell activation or effector function by immunosuppression in organ transplantation using pharmacological immunomodulatory agents[8-10].

Several new strategies have been developed to avoid immune rejection of stem cell-derived grafts. These include the use of novel immunosuppressants[11] and of autologous stem cells drawn from somatic cell nuclear transfer (SCNT) and inducible pluripotent stem cell (iPSC) technology[12,13]. However, little is known about the immune response toward these stem cells because of the lack of human clinical trials with these cells. Here, we discuss a new strategy to overcome the hurdle of immune rejection in stem cell therapy of human diseases.

MECHANISMS OF IMMUNE REJECTION

Immune rejection occurs when a transplanted stem cell is not accepted by the body of a transplant recipient. This is expected to happen, because the immune system is able to distinguish a foreign material within the body and try to destroy it, just as it tries to destroy infecting organisms such as bacteria and viruses[14,15]. Allogeneic graft rejection and organ maintenance are the two primary factors, which render donor organs competitive. To be eligible to receive a donor organ, an individual has to pass several compatibility tests[16]. However, rejections may occur even if a patient passes the needed compatibility tests.

Rejections are classified into three major types based on their severities: hyperacute rejection, acute rejection and chronic rejection. Hyperacute rejection happens within short duration after the transplantation process. Preexisting antibodies, which are reactive to the donor tissue, can cause a series of severe systemic inflammatory responses following by blood clotting. Therefore, the transplanted organ must be removed if hyperacute rejection occurs[17-19]. On the other hand, acute rejection and chronic rejection are less dangerous compared to hyperacute rejection. Acute rejection usually occurs within one week after the transplantation because of human leukocyte antigen system (HLA) antigen mismatch. Chronic rejection refers to mismatched minor histocompatibility complex, resulting in long-term rejection of the graft[20]. Since perfect matches between donor and recipient HLA antigens are rare, donor organ recipients often suffer from acute rejection. According to the Organ Procurement Transplant Network (OPTN) national registry in the United States, about 60%-75% of kidney recipients and 50%-60% of liver recipients will experience acute rejection[21-27]. The only available treatment for acute rejection now is either retransplantation or the use of chemotherapeutic immune suppressant like corticosteroids and calcineurin inhibitors. However, immune suppressants will affect the immune system as a whole and lead to immunocompromise complications.

Immune rejection is mediated through both T cell-mediated (direct) and humoral immune (antibodies, indirect) mechanisms. Direct rejections involve the contact between donor antigen presenting cells (APC) and recipient T cells. Antigens on the surface of donor APC can be recognized as foreign particles by recipient T cells through ligation of co-stimulatory molecules. Indirect rejections involve antigens released into the environment, which can be picked up by the recipient APCs and present to the recipient T cells[12,13]. The number of mismatched alleles determines the speed and magnitude of the rejection response. Different mechanisms act against different grafts.

ESCs and their derivatives express human leukocyte class I antigens (MHC I) and minor histocompatibility antigens, both have the potential to trigger host immune rejection[28]. Additionally, ESC may also differentiate into blood cells that express different ABO blood group antigens, which are also immunogenic. Blood group O is a universal donor, which can be selected to avoid rejections caused by ABO blood group antigen differences. In addition, ESCs also express embryo-specific antigens. These embryo-specific antigens, produced only in the embryo stage are treated as foreign particles in a fully developed human body[12,13].

Expressed xenogeneic proteins derived from culture medium may also be a source of immune rejection[29]. An immune response to these antigens may lead to a late graft loss or hastened rejection of subsequent stem cell grafts[30]. This immune rejection can be overcome either by physical immunoprotection of stem cells provided by polymer encapsulation[31-33] or by purification of stem cells before transplantation[34]. Alternative methods to eliminate this potential problem include growing cells in a serum-free medium[35-38].

TWISTING THE IMMUNE RESPONSES

The simplest way to avoid rejection is to use autologous adult stem cells (autologous bone marrow derived mesenchymal stem cells) instead of ESCs which are derived from embryos. Autologous adult stem cells express antigens identical with the hosts’ cells and therefore are not subject to the rejections. However, it is difficult to isolate a sufficient amount of adult stem cells[39]. Ex vivo expansion and differentiation of adult stem cells are another major challenge and roadblock for adult stem cell therapy[39]. Purifying adult stem cells from diseased cells (such as autologous bone marrow transplantation) is also technically difficult. Various methods such as SCNT and iPSC technology have been developed to yield sufficient amounts of patient-specific stem cells for cell therapy. However, these methods have not yet been achieved for the status of clinical application.

Manipulating the central self-tolerance pathway is a more immediately available approach for stem cell therapy[28]. There are two types of self-tolerance: central self-tolerance and peripheral self-tolerance[12,13]. Central self-tolerance refers to negative selection of T regulatory cells and T cells within the thymus. Under normal circumstances, T cells differentiated within the thymus do not leave the thymus immediately. Instead, they undergo a process called negative selection, which deletes the host-reactive T cells before releasing them into the circulation. On the other hand, peripheral self-tolerance refers to inappropriate co-stimulation between APCs and T cells which lead to failure to launch proper responses (inflammatory).

Technically, host-donor chimerism can be created to introduce self-tolerance to the donor cells with two steps. First, we can restore thymic function for T-cell selection in host. Second, we need to introduce donor cells into host thymus to delete T-cells that recognize donor antigens[40]. The thymus shrinks during puberty because of increasing production of sex hormones, and its functions are affected[41-44]. Therefore, thymic functions must be restored in order to manipulate self- tolerance in adults. The following strategy can be applied: first, sex steroid inhibitory drug (LHRH-A) can be used in combination with thymic growth factors including KGF, IL-7 and FLT3 to restore adult thymic functions[45]. Second, antigens derived from donor cells must be introduced into the restored thymus[46]. Hematopoietic stem cells (HSCs) can be used to deliver donor cell antigens since they have preferential access to the thymus[46]. However, injecting a large quantity of HSC may trigger serious graft-versus-host diseases, which result in side effects including hemolysis, lost of lymphocytes and possibly damaged tissues because of reactive donor T-cells. Therefore, direct injection is not ideal and an alternative method must be developed to avoid serious graft-versus-host diseases while supplying the HSC steadily to the restored thymus[47,48].

After introducing antigen, a phenomenon called mixed chimerism may occur within the thymus and the donor reactive T cells could be deleted by negative selection[49-52]. Also, T-regulatory cells formed from the thymus may migrate into the circulation and arrest those donor reactive T-cells in the circulation. This immune tolerance has been reported in experiments with mouse skin grafts[53-60].

In animal models, gradually introducing donor cells is a possible approach to create desirable chimeras for thymus restoration. Our previous study on tissue regeneration during mouse pregnancy showed that fetal stem cells repaired maternal skin injury and created fetal-maternal microchimerism[61]. This study suggests that slow release of stem cells that are minimally immunogenic could be used as an alternative method to create chimeras for donor specific immune tolerance. In another study of mouse hematopoietic stem cells, we used intraosseous infusion, a process of injection directly into the marrow of the bone, for introducing HSC into mouse[62]. Intraosseous infusion of HSC allows cells to home to bone marrow more efficiently and avoids circulating large amount of donor cells in recipient blood. This dramatically lessens the chance of immune rejection and may lead to more effective creation of chimerism[61,62].

CLINICAL SUCCESSES FOR MANIPULATING SELF-TOLERANCE

In humans, naturally occurring mixed chimerism self-tolerance has been reported[63]. In one case, a nine-year-old girl who acquired acute fulminant hepatitis from viral infection was given a liver transplant. However, the donor was a 12 year-old boy who died of brain injury having different HLA antigens (A34, 68; B50, 76; DR4, 13) from the girl’s (A2, 24; B37, 62; DR7, 9). In addition, their blood types were also different. The girl was type O, RhD-negative but the boy was type O RhD-positive.

The allograft was thought to have a high potential for triggering acute and chronic rejections, which eventually might lead to destruction of the graft. Additionally both of them were cytomegalovirus positive, which may have negative effects on the immunocompromised patient. However, the liver was still transplanted since benefit was determined to be greater than the risk. Standard immunotherapy including tacrolimus and methylprednisolone was given to the girl after the transplantation. Ganciclovir was also given to the girl to try to get rid of the cytomegalovirus. Only 13 d after the transplantation, acute rejection was noted by acute biliary obstruction. The surgical formation of a communication between the common bile duct and the duodenum was performed. The immunosuppressant drugs were given continuously.

The girl suffered from moderate lymphopenia (lymphocyte count, 0.5 × 109 per liter) and anemia until about nine months after the transplantation. Her red blood cell and lymphocyte counts decreased while the white blood cell counts increased, which suggested that her B cells were making antibodies targeting the donor red blood cells resulting in hemolysis. Interestingly, her blood type changed from RhD-negative to RhD-positive, which was the donor’s blood type nine months after the transplantation was given. The change showed she developed mix chimerism, which was possibly because of hematopoietic stem cells migrating from the allogeneic graft to the thymus. Therefore the physicians decided to do a series of follow-up studies including analysis of XY chromosomes on the hematopoietic cells. The result was astonishing, 94% of her T cells, 98% of her B cells and 100% of her natural killer cells had XY chromosomes. The appearance of XY chromosomes on those cells was strong evidence suggesting HSC from the allogenetic graft had successfully migrated into her thymus and proliferated since the female only had XX chromosomes[64]. The surgeons then withdrew the immunosuppressive drug gradually to see if full engraftment could be achieved. The girl remained healthy for the next five years without any sign of rejection. Her liver was functioning normally, and her HLA antigen changed to the donor’s type. In this case, the infection with cytomegaloviruses (CMV) in combination with her young age, may have resulted in a more immunocompromised state allowing the full engraftment to be achieved before the graft-versus-host diseases became lethal[63]. In such cases, intraosseous infusion of HSC may be a practical method to create the host-donor tolerance for following organ transplantation or stem cell therapy.

Another successful case was from a recipient of combined kidney and hematopoietic-cell transplants from an HLA-matched donor[65]. There was no rejection or clinical manifestations of graft-versus-host disease without immunosuppressive drugs for more than 24-mo post-transplantation. The blood analyses showed that the patient had persistent mixed chimerism and the function of the kidney allograft was normal.

CLINICAL IMPLICATION

The above case studies suggest that donor-host chimerism can be used to overcome tissue and organ rejection, and slowly introducing donor antigens into host is important to create such chimerism.

Twisting immune responses for allogeneic graft rejection will benefit millions of people worldwide. According to the OPTN (The Organ Procurement and Transplantation Network), there were about 400 000 allogeneic graft recipients in the United States of America alone during the last two decades. In addition, 100 000 patients were queuing on transplant waiting lists for various types of donor organs[26]. Unfortunately, donor organs are competitively allocated, and sometimes it takes years of waiting for an individual to finally be able to receive the donor organ. Sadly, some patients just cannot wait for that long with a dysfunctional organ.

Management of the central self-tolerance pathway provides a possible solution for not only stem cell therapy but all organ transplantation[66]. For example, the use of allogeneic “universal donor” mesenchymal stromal cells (MSCs) may be a great clinical convenience for treatment of autoimmune ailments such as multiple sclerosis[67]. The strategy of manipulating the central self-tolerance pathway may be able to change the appearance of modern clinical science and eventually benefit almost every individual worldwide.

FUTURE DIRECTIONS

The current objective is to reproduce mixed chimerism artificially within an adult with the use of HSCs and immunosuppressive drugs that can restore thymic functions. However, there are still some barriers, which need to be solved before a full engraftment can occur in an adult. Since the thymus atrophies during aging, a sex steroid inhibitory drug (LHRH-A) should be use in combination with thymic growth factors including KGF, IL-7 and FLT3 to restore adult thymic functions[43,68]. After restoration of thymic functions, HSCs need to be introduced into the thymus. Direct injection of HSC and its downstream progenitors (differentiated T cells/T regulatory cells) to the thymus in combination with immunosuppressive drugs (like tacrolimus and methylprednisolone) may allow time to eliminate donor reactive lymphocytes. This also reduces the risk and the severity of hemolysis caused by donor T-cells to the recipient red blood cells or vice versa.

In summary, host-donor chimerism can be used to introduce a specific tolerance for donor tissues. Such a self-tolerance not only makes stem cell therapy one step closer to reality, but also makes organ transplantation available for many patients who cannot find matching donors.

Footnotes

Supported by CHOC Children’s Foundation and CHOC Neuroscience Institute (to Li SC) and NIH grant 1R21CA134391-01A1 (to Zhong JF)

Peer reviewers: Domenico Capone, MD, Department of Neurosciences, Unit of Clinical Pharmacology, School of Medicine, Federico II University, Via S. Pansini 5, 80131 Naples, Italy; Philippe Bourin, MD, PhD, Laboratoire de thérapie cellulaire, EFS-PM, 75 rue de Lisieux, Toulouse, 31300, France

S- Editor Li LF L- Editor Lalor PF E- Editor Lin YP

References

1. Damjanov I. The road from teratocarcinoma to human embryonic stem cells. Stem Cell Rev. 2005;1:273–276. [PubMed]
2. Swartzendruber DE, Friedrich TD, Lehman JM. Resistance of teratocarcinoma stem cells to infection with simian virus 40: early events. J Cell Physiol. 1977;93:25–30. [PubMed]
3. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, Paz N, Koren-Michowitz M, Waldman D, Leider-Trejo L, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009;6:e1000029. [PMC free article] [PubMed]
4. Swijnenburg RJ, Schrepfer S, Cao F, Pearl JI, Xie X, Connolly AJ, Robbins RC, Wu JC. In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation. Stem Cells Dev. 2008;17:1023–1029. [PMC free article] [PubMed]
5. Swijnenburg RJ, Schrepfer S, Govaert JA, Cao F, Ransohoff K, Sheikh AY, Haddad M, Connolly AJ, Davis MM, Robbins RC, et al. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci USA. 2008;105:12991–12996. [PubMed]
6. Swijnenburg RJ, van der Bogt KE, Sheikh AY, Cao F, Wu JC. Clinical hurdles for the transplantation of cardiomyocytes derived from human embryonic stem cells: role of molecular imaging. Curr Opin Biotechnol. 2007;18:38–45. [PubMed]
7. Preynat-Seauve O, de Rham C, Tirefort D, Ferrari-Lacraz S, Krause KH, Villard J. Neural progenitors derived from human embryonic stem cells are targeted by allogeneic T and natural killer cells. J Cell Mol Med. 2009:Epub ahead of print. [PubMed]
8. Halloran PF. Molecular mechanisms of new immunosuppressants. Clin Transplant. 1996;10:118–123. [PubMed]
9. Perico N, Remuzzi G. Prevention of transplant rejection: current treatment guidelines and future developments. Drugs. 1997;54:533–570. [PubMed]
10. Auletta JJ, Cooke KR. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease. Curr Opin Pediatr. 2009;21:30–38. [PubMed]
11. Fletcher AL, Lowen TE, Sakkal S, Reiseger JJ, Hammett MV, Seach N, Scott HS, Boyd RL, Chidgey AP. Ablation and regeneration of tolerance-inducing medullary thymic epithelial cells after cyclosporine, cyclophosphamide, and dexamethasone treatment. J Immunol. 2009;183:823–831. [PubMed]
12. Chidgey AP, Layton D, Trounson A, Boyd RL. Tolerance strategies for stem-cell-based therapies. Nature. 2008;453:330–337. [PubMed]
13. Chidgey AP, Seach N, Dudakov J, Hammett MV, Boyd RL. Strategies for reconstituting and boosting T cell-based immunity following haematopoietic stem cell transplantation: pre-clinical and clinical approaches. Semin Immunopathol. 2008;30:457–477. [PubMed]
14. Graber JJ, Dhib-Jalbut S. Protective autoimmunity in the nervous system. Pharmacol Ther. 2009;121:147–159. [PubMed]
15. Schwartz M. Protective autoimmunity as a T-cell response to central nervous system trauma: prospects for therapeutic vaccines. Prog Neurobiol. 2001;65:489–496. [PubMed]
16. Fändrich F, Lin X, Chai GX, Schulze M, Ganten D, Bader M, Holle J, Huang DS, Parwaresch R, Zavazava N, et al. Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning. Nat Med. 2002;8:171–178. [PubMed]
17. Jatene MB, Miana LA, Pessoa AJ, Riso A, Azeka E, Tanamati C, Gimenez S, Lopes AA, Marcial MB, Stolf NA. Pediatric heart transplantation in refractory cardiogenic shock: a critical analysis of feasibility, applicability and results. Arq Bras Cardiol. 2008;90:329–333. [PubMed]
18. Higgins PD, Umar RK, Parker JR, DiMagno MJ. Massive lower gastrointestinal bleeding after rejection of pancreatic transplants. Nat Clin Pract Gastroenterol Hepatol. 2005;2:240–244; quiz 1 p following 244. [PubMed]
19. Pollak R, Blanchard JM. Organ donor or graft pretreatment to prolong allograft survival: lessons learned in the murine model. Transplantation. 2000;69:2432–2439. [PubMed]
20. Krishnan NS, Higgins RM, Lam FT, Kashi H, Jobson S, Ramaiyan K, Rahman M, Morris A. HA-1 mismatch has significant effect in chronic allograft nephropathy in clinical renal transplantation. Transplant Proc. 2007;39:1439–1445. [PubMed]
21. Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation. 2009;87:1019–1026. [PubMed]
22. Gill J, Shah T, Hristea I, Chavalitdhamrong D, Anastasi B, Takemoto SK, Bunnapradist S. Outcomes of simultaneous heart-kidney transplant in the US: a retrospective analysis using OPTN/UNOS data. Am J Transplant. 2009;9:844–852. [PubMed]
23. Gritsch HA, Veale JL, Leichtman AB, Guidinger MK, Magee JC, McDonald RA, Harmon WE, Delmonico FL, Ettenger RB, Cecka JM. Should pediatric patients wait for HLA-DR-matched renal transplants? Am J Transplant. 2008;8:2056–2061. [PubMed]
24. Magee JC, Krishnan SM, Benfield MR, Hsu DT, Shneider BL. Pediatric transplantation in the United States, 1997-2006. Am J Transplant. 2008;8:935–945. [PubMed]
25. Nikaein A, Cherikh W, Nelson K, Baker T, Leffell S, Bow L, Crowe D, Connick K, Head MA, Kamoun M, et al. Organ procurement and transplantation network/united network for organ sharing histocompatibility committee collaborative study to evaluate prediction of crossmatch results in highly sensitized patients. Transplantation. 2009;87:557–562. [PubMed]
26. Sung RS, Galloway J, Tuttle-Newhall JE, Mone T, Laeng R, Freise CE, Rao PS. Organ donation and utilization in the United States, 1997-2006. Am J Transplant. 2008;8:922–934. [PubMed]
27. Waki K, Kadowaki T. An analysis of long-term survival from the OPTN/UNOS Pancreas Transplant Registry. Clin Transpl. 2007:9–17. [PubMed]
28. Burt RK, Verda L, Kim DA, Oyama Y, Luo K, Link C. Embryonic stem cells as an alternate marrow donor source: engraftment without graft-versus-host disease. J Exp Med. 2004;199:895–904. [PMC free article] [PubMed]
29. Müller WE, Perovic S, Wilkesman J, Kruse M, Müller IM, Batel R. Increased gene expression of a cytokine-related molecule and profilin after activation of Suberites domuncula cells with xenogeneic sponge molecule(s) DNA Cell Biol. 1999;18:885–893. [PubMed]
30. Swijnenburg RJ, Tanaka M, Vogel H, Baker J, Kofidis T, Gunawan F, Lebl DR, Caffarelli AD, de Bruin JL, Fedoseyeva EV, et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation. 2005;112:I166–I172. [PubMed]
31. Schwenter F, Schneider BL, Pralong WF, Déglon N, Aebischer P. Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions. Hum Gene Ther. 2004;15:669–680. [PubMed]
32. Zhang H, Zhu SJ, Wang W, Wei YJ, Hu SS. Transplantation of microencapsulated genetically modified xenogeneic cells augments angiogenesis and improves heart function. Gene Ther. 2008;15:40–48. [PubMed]
33. Sefton MV, May MH, Lahooti S, Babensee JE. Making microencapsulation work: conformal coating, immobilization gels and in vivo performance. J Control Release. 2000;65:173–186. [PubMed]
34. Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, Fassas A, Tindle S, Nelson J, Juttner C, et al. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood. 1998;91:4489–4495. [PubMed]
35. Hisamatsu-Sakamoto M, Sakamoto N, Rosenberg AS. Embryonic stem cells cultured in serum-free medium acquire bovine apolipoprotein B-100 from feeder cell layers and serum replacement medium. Stem Cells. 2008;26:72–78. [PubMed]
36. Bernardo ME, Avanzini MA, Perotti C, Cometa AM, Moretta A, Lenta E, Del Fante C, Novara F, de Silvestri A, Amendola G, et al. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol. 2007;211:121–130. [PubMed]
37. Ramadan G, Schmidt RE, Schubert J. In vitro generation of human CD86+ dendritic cells from CD34+ haematopoietic progenitors by PMA and in serum-free medium. Clin Exp Immunol. 2001;125:237–244. [PubMed]
38. Müller G, Müller A, Jonuleit H, Steinbrink K, Szalma C, Paragnik L, Lingnau K, Schmidt E, Knop J, Enk AH. Fetal calf serum-free generation of functionally active murine dendritic cells suitable for in vivo therapeutic approaches. J Invest Dermatol. 2000;114:142–149. [PubMed]
39. Li SC, Wang L, Jiang H, Acevedo J, Chang AC, Loudon WG. Stem cell engineering for treatment of heart diseases: potentials and challenges. Cell Biol Int. 2009;33:255–267. [PubMed]
40. Ildstad ST, Wren SM, Bluestone JA, Barbieri SA, Sachs DH. Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med. 1985;162:231–244. [PMC free article] [PubMed]
41. Heng TS, Goldberg GL, Gray DH, Sutherland JS, Chidgey AP, Boyd RL. Effects of castration on thymocyte development in two different models of thymic involution. J Immunol. 2005;175:2982–2993. [PubMed]
42. Flores KG, Li J, Sempowski GD, Haynes BF, Hale LP. Analysis of the human thymic perivascular space during aging. J Clin Invest. 1999;104:1031–1039. [PMC free article] [PubMed]
43. Goldberg GL, Sutherland JS, Hammet MV, Milton MK, Heng TS, Chidgey AP, Boyd RL. Sex steroid ablation enhances lymphoid recovery following autologous hematopoietic stem cell transplantation. Transplantation. 2005;80:1604–1613. [PubMed]
44. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS, Blazar BR, Millar JL, Malin MA, Chidgey AP, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol. 2005;175:2741–2753. [PubMed]
45. Rossi SW, Jeker LT, Ueno T, Kuse S, Keller MP, Zuklys S, Gudkov AV, Takahama Y, Krenger W, Blazar BR, et al. Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. Blood. 2007;109:3803–3811. [PubMed]
46. Seggewiss R, Loré K, Guenaga FJ, Pittaluga S, Mattapallil J, Chow CK, Koup RA, Camphausen K, Nason MC, Meier-Schellersheim M, et al. Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood. 2007;110:441–449. [PubMed]
47. Statkute L, Oyama Y, Barr WG, Sufit R, Ho S, Verda L, Loh Y, Yaung K, Quigley K, Burt RK. Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis. Ann Rheum Dis. 2008;67:991–997. [PubMed]
48. Verda L, Kim DA, Ikehara S, Statkute L, Bronesky D, Petrenko Y, Oyama Y, He X, Link C, Vahanian NN, et al. Hematopoietic mixed chimerism derived from allogeneic embryonic stem cells prevents autoimmune diabetes mellitus in NOD mice. Stem Cells. 2008;26:381–386. [PubMed]
49. Alwayn IP, Buhler L, Appel JZ 3rd, Goepfert C, Csizmadia E, Correa L, Harper D, Kitamura H, Down J, Awwad M, et al. Mechanisms of thrombotic microangiopathy following xenogeneic hematopoietic progenitor cell transplantation. Transplantation. 2001;71:1601–1609. [PubMed]
50. Vanikar AV, Modi PR, Patel RD, Kanodia KV, Shah VR, Trivedi VB, Trivedi HL. Hematopoietic stem cell transplantation in autoimmune diseases: the Ahmedabad experience. Transplant Proc. 2007;39:703–708. [PubMed]
51. Wysoczanska B, Bogunia-Kubik K, Dlubek D, Jaskula E, Sok A, Drabczak-Skrzypek D, Sedzimirska M, Lange A. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse. Transplant Proc. 2007;39:2898–2901. [PubMed]
52. Zhang JL, Cai J, Jackson JD, Walls S, Kuszynski CA, Fox IJ. Competitive equality of donor cells expressing a disparate MHC antigen following stem cell-enriched bone marrow transplantation. Transplantation. 2005;79:1332–1337. [PubMed]
53. Joffre O, Santolaria T, Calise D, Al Saati T, Hudrisier D, Romagnoli P, van Meerwijk JP. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med. 2008;14:88–92. [PMC free article] [PubMed]
54. Shaaban AF, Kim HB, Gaur L, Liechty KW, Flake AW. Prenatal transplantation of cytokine-stimulated marrow improves early chimerism in a resistant strain combination but results in poor long-term engraftment. Exp Hematol. 2006;34:1278–1287. [PMC free article] [PubMed]
55. Lee EN, Lee J, Kim EY, Park HJ, Chang CY, Jung DY, Choi SY, Lee SK, Kwon CH, Joh JW, et al. Tolerance induction through megadose bone marrow transplantation with two-signal blockade. J Surg Res. 2006;130:102–109. [PubMed]
56. Laylor R, Dewchand H, Simpson E, Dazzi F. Engraftment of allogeneic hematopoietic stem cells requires both inhibition of host-versus-graft responses and 'space' for homeostatic expansion. Transplantation. 2005;79:1484–1491. [PubMed]
57. Deng W, Han Q, Liao L, Li C, Ge W, Zhao Z, You S, Deng H, Zhao RC. Allogeneic bone marrow-derived flk-1+Sca-1- mesenchymal stem cells leads to stable mixed chimerism and donor-specific tolerance. Exp Hematol. 2004;32:861–867. [PubMed]
58. Sembeil R, Sanhadji K, Vivier G, Chargui J, Touraine JL. Prolonged survival of mouse skin allografts after transplantation of fetal liver cells transduced with hIL-10 gene. Transpl Immunol. 2004;13:1–8. [PubMed]
59. Ploemacher RE, Johnson KW, Rombouts EJ, Etienne K, Westerhof GR, Baumgart J, White-Scharf ME, Down JD. Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model. Biol Blood Marrow Transplant. 2004;10:236–245. [PubMed]
60. Abe M, Qi J, Sykes M, Yang YG. Mixed chimerism induces donor-specific T-cell tolerance across a highly disparate xenogeneic barrier. Blood. 2002;99:3823–3829. [PubMed]
61. Alexander SI, Smith N, Hu M, Verran D, Shun A, Dorney S, Smith A, Webster B, Shaw PJ, Lammi A, et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med. 2008;358:369–374. [PubMed]
62. Matulis M, High KP. Immune reconstitution after hematopoietic stem-cell transplantation and its influence on respiratory infections. Semin Respir Infect. 2002;17:130–139. [PubMed]
63. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med. 2008;358:362–368. [PubMed]
64. Sutherland JS, Spyroglou L, Muirhead JL, Heng TS, Prieto-Hinojosa A, Prince HM, Chidgey AP, Schwarer AP, Boyd RL. Enhanced immune system regeneration in humans following allogeneic or autologous hemopoietic stem cell transplantation by temporary sex steroid blockade. Clin Cancer Res. 2008;14:1138–1149. [PubMed]
65. Rafei M, Birman E, Forner K, Galipeau J. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther. 2009;17:1799–1803. [PubMed]
66. Min D, Panoskaltsis-Mortari A, Kuro-O M, Holländer GA, Blazar BR, Weinberg KI. Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. Blood. 2007;109:2529–2537. [PubMed]
67. Zhong JF, Weiner LP. Role of fetal stem cells in maternal tissue regeneration. Gene Regul Syst Bio. 2007;1:111–115. [PMC free article] [PubMed]
68. Zhong JF, Zhan Y, Anderson WF, Zhao Y. Murine hematopoietic stem cell distribution and proliferation in ablated and nonablated bone marrow transplantation. Blood. 2002;100:3521–3526. [PubMed]

Articles from World Journal of Stem Cells are provided here courtesy of Baishideng Publishing Group Inc